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ABSTRACT: The increasing emergence of drug-resistant fungal
pathogens, together with the limited number of available antifungal
drugs, presents serious clinical challenges to treating systemic, life-
threatening infections. Repurposing existing drugs to augment the
antifungal activity of well-tolerated antifungals is a promising
antifungal strategy with the potential to be implemented rapidly.
Here, we explored the mechanism by which colistin, a positively
charged lipopeptide antibiotic, enhances the antifungal activity of
fluconazole, the most widely used orally available antifungal. In a
range of susceptible and drug-resistant isolates and species, colistin was primarily effective at reducing fluconazole tolerance, a
property of subpopulations of cells that grow slowly in the presence of a drug and may promote the emergence of persistent
infections and resistance. Clinically relevant concentrations of colistin synergized with fluconazole, reducing fluconazole minimum
inhibitory concentration 4-fold. Combining fluconazole and colistin also increased survival in a C. albicans Galleria mellonella
infection, especially for a highly fluconazole-tolerant isolate. Mechanistically, colistin increased permeability to fluorescent antifungal
azole probes and to intracellular dyes, accompanied by an increase in cell death that was dependent upon pharmacological or genetic
inhibition of the ergosterol biosynthesis pathway. The positive charge of colistin is critical to its antifungal, and antibacterial, activity:
colistin directly binds to several eukaryotic membrane lipids (i.e., L-α-phosphatidylinositol, L-α-phosphatidyl-L-serine, and L-α-
phosphatidylethanolamine) that are enriched in the membranes of ergosterol-depleted cells. These results support the idea that
colistin binds to fungal membrane lipids and permeabilizes fungal cells in a manner that depends upon the degree of ergosterol
depletion.
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Candidemia, the fourth most common hospital-acquiredinfection in the United States, is associated with an
attributable mortality of up to 40%1 and is most frequently
caused by Candida albicans (38%).2 Only three classes of
antifungal drugs are used systemically, largely because of the
paucity of fungal-specific drug targets. Repurposing known
drugs (e.g., chemosensitizers) that are able to synergize with
existing antifungal drugs is an approach for the rapid
development of improved therapeutic strategies.3,4
The azoles, the most commonly used antifungal drug class,5
target the biosynthesis of ergosterol (a sterol not found in
animals or plants), by inactivating lanosterol 14α-demethylase,
which is encoded by the ERG11 gene.6 Fluconazole is the most
commonly used azole antifungal and is fungistatic rather than
fungicidal for yeasts.5 Emerging species with higher levels of
fluconazole resistance (e.g., Candida glabrata and Candida
auris) are increasingly prevalent.5 In addition, susceptible
isolates can have high levels of fluconazole tolerance, which
appears to reduce the efficacy of fluconazole monotherapy.7,8
Antifungal resistance is the ability to grow normally in the
presence of drug at concentrations that inhibit other isolates of
a given species, which is usually due to genetic changes that
affect all cells in the population. Mechanisms of antifungal
resistance include those that prevent or inhibit binding of the
drug to its target, including reduction in target affinity, and
decreased intracellular drug concentration due to membrane
permeability changes and/or drug efflux.9 Clinical breakpoints
identify isolates whose minimal inhibitory concentration
(MIC) exceeds the drug concentration reached during
treatment (reviewed in ref 8).
Antifungal tolerance is the ability of some cells in the
population to grow slowly despite high drug concentrations
and is characterized by slow growth of a subpopulation of cells
after 48 h of growth in drug, where resistance is generally
evident after 24 h in the same conditions. Since standard
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clinical assays measure growth at 24 h, strains with tolerance
are classified as drug-susceptible. Tolerance is measured, where
the fraction of growth (FoG) is quantitated as the degree of
growth within vs outside the zone of inhibition.10 Alternatively,
tolerance can be quantitated using broth microdilution
assays.7,10 The level of tolerance in a given isolate is
reproducible and differs from that in other isolates. This is
presumably due to differences in genetic backgrounds, as
multiple stress response pathways contribute to tolerance.7
However, within a given genetic isolate, the responses of
individual cells differ, such that the tolerance response is
generally considered to be physiological, or epigenetic, rather
than a genetic change.8 Several recent studies suggest high
levels of tolerance have a negative effect on clinical
outcomes.7,11,12
A common drug-resistance mechanism is hyperactivation of
efflux pumps, although drug uptake rates may also affect the
efficacy of antifungal drugs that target intracellular molecules.
Several studies suggest that azoles enter cells via passive
diffusion because cells with higher membrane fluidity were
more susceptible to the drug.13−15 Earlier studies of azole
uptake in C. albicans utilized tritiated fluconazole ([3H]-FLC)
and ketoconazole ([3H]-KTZ)16,17 to measure intracellular
drug content, which reflects the balance between drug uptake,
and drug efflux. Internalization of the tritiated drugs occurred
rapidly in live, but not dead cells, while dead cells accumulated
propidium iodide stain.16 In glucose-depleted, de-energized
cells, [3H]-FLC accumulated and reached saturation, and
competition assays suggested that the same transporter is used
for different azole antifungals. Taken together, these data
suggested that the mechanism of drug uptake was not via
passive diffusion.16
Several adjuvant drugs, when used together with fluconazole,
reduce tolerance to background levels without having a major
effect on drug resistance (MIC).4 These include drugs that
affect the calcineurin pathway, Hsp90 activity, the target of
rapamycin (TOR) pathway and other stress responses.18
Importantly, adding any one of these adjuvants to fluconazole
(a fungistatic drug) renders it fungicidal: cells exposed to
supra-MIC FLC concentrations together with the adjuvant do
not survive.7 Thus, a number of drugs sensitize Candida cells
to fluconazole by modulating their stress response pathways.
Colistin, also known as polymyxin E, belongs to the
lipopeptide class of antibiotics (with polymyxin B being the
other polymyxin used clinically) and targets lipopolysacchar-
ides within the membranes of Gram-negative bacteria.19 It is a
cationic cyclic polypeptide with a hydrophobic fatty acid acyl
chain that interacts electrostatically with the anionic phosphate
groups of the lipid A core of lipopolysaccharide (LPS)
molecules in the outer leaflet of the outer membrane of
Gram-negative bacteria.20,21 Colistin is increasingly used to
treat multidrug-resistant Gram-negative bacterial infections22
despite its nephrotoxicity and neurotoxicity.23 By competitively
displacing divalent cations (Ca2+ and Mg2+) from the
phosphate groups of membrane lipids, colistin targets LPS in
the outer membrane replacing the bivalent cations that
stabilize the outer leaflet of the outer membrane groups,
resulting in membrane leakage and bacterial death.24−26
Colsitin is generally not considered an antifungal drug,
although it has weak antifungal activity in Candida tropicalis27
and when used in combination with the azole isavuconazole in
C. auris.28
Colistin was reported to synergize with azole antifungals
against Candida and Cryptococcal isolates.29,30 However, prior
studies used high levels of colistin that are not readily achieved
in patients.27,31,32 For example, C. albicans cidality was
reported with 6−8 μg/mL polymyxin B added to 64 μg/mL
fluconazole, which is well above the concentration that is
reached in patients.30 Furthermore, the mechanism(s) by
which colistin synergizes with azoles is not known: Do they
work on eukaryotes via mechanism(s) like those that confer
antibacterial activity? And why are they synergistic with the
azole antifungals?
Here, we studied how colistin synergizes with azole
antifungals. We found that this synergism caused a major
reduction in azole tolerance both in vitro and in vivo with only
a modest effect on antifungal resistance at concentrations that
are clinically relevant. Importantly, the mechanism of action of
colistin is membrane permeabilization and subsequent cell
death in cells that are depleted for ergosterol, either by azole
drug treatment or by mutations in the ergosterol biosynthesis
pathway.
■ RESULTS
Combining Fluconazole and Colistin (FLC+COL)
Reduces Drug Tolerance and Resistance in C. albicans
Isolates and Other Pathogenic Yeasts. Colistin (COL) is
known to enhance the antifungal efficacy of fluconazole (FLC),
but whether this is largely due to a reduction in drug resistance
or tolerance is unclear. Using disk diffusion assays with FLC
(25 μg) in the disk and COL (64 μg/mL) in the agar medium,
we measured both resistance/susceptibility and tolerance to
FLC using diskImageR,10 an image analysis pipeline that
quantifies resistance/susceptibility as the radius (in mm) of the
zone of inhibition at 20% inhibition (RAD20) after 24 h and
the fraction of growth (FoG20) within the zone of inhibition at
48 h.7,10 The addition of COL reduced FoG20 to background
levels, (i.e., levels seen with very low tolerance strains), while
RAD20 increased only modestly (by ∼3.5 mm) (Figure 1A and
B). Thus, combining COL with FLC primarily reduced
tolerance in strain SC5314, the standard lab strain.
To determine the generalizability of the effect, we performed
similar analyses on a collection of clinical isolates representing
the four major C. albicans clades, which exhibit FLC tolerance
levels measured as FoG ranging from <30% to >80%7 (Figure
1C). Notably, COL cleared FoG to near-baseline levels, in a
manner that correlated with the initial FoG levels (Figure 1C)
(FoG levels for FLC vs FLC+COL, with coefficient of
determination (R2) of 0.92. COL+FLC had a similar effect
in C. albicans strains reported to be resistant to FLC as well as
for representative isolates from other pathogenic species and
for wild isolates of Saccharomyces cerevisiae (Figure S1), causing
a slight increase in RAD/susceptibility and dramatic clearance
of FoG/tolerance). Thus, COL appears to affect very different
yeast strains in an analogous manner.
Effect of Colistin on Other Antifungal Drugs. Because
COL was reported to affect several antifungal drugs, we first
tested the degree to which COL enhanced the activity of azole
drugs that, like FLC, inhibit sterol biosynthesis. Like with FLC,
COL added to ketoconazole, itraconazole, posaconazole or
miconazole only slightly increased the susceptibility level (2−5
mm) (Figure S2) and cleared FoG20 to baseline levels.
Interestingly, with terbinafine, a drug that inhibits Erg1
catalysis, the first step in the ergosterol biosynthesis pathway,
COL completely eliminated FoG and increased susceptibility
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(RAD20) by 7 mm (Figure S2C). By contrast, we detected only
minor effects of COL on the resistance levels of echinocandin
and polyene classes of antifungal drugs. In addition, there was
little effect of COL on sphingolipid inhibitors and on 5-
fluorocytosine, an inhibitor of nucleotide biosynthesis (Figure
S3). Thus, colistin appears to have a minor effect on resistance
to most antifungal agents, and a more dramatic effect on azole
tolerance.
Colistin Acts Synergistically with Antifungal Tria-
zoles. We next asked whether the effect of COL on FLC is
synergistic or additive, using checkerboard assays.33 The two
drugs were combined in a series of 2-fold dilutions from 0 to
128 μg (Figure 2A). In combination with 0.25 μg/mL FLC, 2
μg COL was sufficient to reduce growth 2-fold and adding 8
μg/mL COL reduced growth by 4-fold (Figure 2B). The FICI
(fraction inhibitory concentration index) value was 0.31 for
0.125 μg/mL FLC and 8 μg/mL COL, which is well within the
range of clinically relevant concentrations and indicates
synergy (FICI < 0.5).34,35 This FICI value (0.31) was higher
than that measured for 0.125 μg/mL COL used together with
0.39 μg/mL of echinocandin (caspofungin) in C. albicans
(FICI = 0.2629). Similarly, for itraconazole and COL, FICI =
0.28 was measured (Table 1, 0.125 μg/mL itraconazole, 4 μg/
mL of COL) (Figure S4). Thus, COL is synergistic with
different antifungal triazoles at levels of both drugs that are
clinically achieveable.36,37
Combination Therapy Using Colistin with Flucona-
zole Increased Cidality. We next asked if COL, like other
adjuvants that eliminate tolerance, increases the level of FLC
cidality in vitro,7 using two approaches. First, we tested if cells
in the zone of inhibition could resume growth by replica-
plating disk diffusion assay plates to rich medium (YPD)
without either drug (Figure 1D). Cells on plates exposed only
to the FLC disk produced a lawn of cells within, as well as
outside, the zone of inhibition, consistent with the static nature
of FLC alone. By contrast, the disk diffusion assays plates that
had included COL, when replica-plated to rich medium, were
essentially clear within the zone of inhibition (Figure 1D),
indicating that the cells treated with inhibitory concentrations
of FLC were unable to regrow in the absence of the drug and
were likely dead. Similar results were seen when COL was
added to other inhibitors of sterol biosynthesis (Figure S2C).
Thus, COL caused the death of cells exposed to azoles and
other inhibitors of sterol biosynthesis, an essential process.
Second, we analyzed cells with propidium iodide (PI), a
common indicator of cell death:38 Control live cells (no drug)
excluded PI, and dead cells (killed with ethanol) stained very
brightly with the dye. Both live and dead controls were used to
set gating thresholds for flow cytometric analysis (Figure 2C):
live cells had no detectable PI (less than ∼250 arbitrary units
(A.U) of fluorescence). Dead cells stained brightly with PI
(>8500 and up to 4.67 × 105 AU of fluorescence), with 99.2%
having PI > 8931 AU.
The proportion of cells in each category was determined
after 24 h of exposure to combinations of both drugs at
concentrations ranging from 0 to 128 μg/mL, as in the
checkerboard assay (Figure 2A). Consistent with results from
the initial checkerboard assay, the number of cells counted per
200 μL reflected the OD600 measurements observed in the
checkerboard in Figure 2A. The number of dead cells increased
when FLC and COL were combined (Figure 2C, Red). These
data support the idea that COL together with FLC not only
inhibits cell growth but also increases cell death at inhibitory
FLC concentrations (Figure 2C, red).
Combination of Fluconazole and Colistin Resulted in
Enhanced Survival Relative to Fluconazole Monother-
apy in Galleria mellonella. We then used the C. albicans−G.
mellonella pathosystem to test FLC+COL efficacy in vivo for
strains with different tolerance levels. G. mellonella were
infected with a dose of C. albicans that gradually killed the
larvae over a period of 5 days. Two hours post inoculation,
larvae were treated with either water (control), FLC, COL, or
FLC+COL as a single dose (Figure 2D−F). Five day survival
of the controls (for all three strains) was only 16−22%.
Survival of larvae infected with the high FoG strain and treated
with FLC+COL (78%) was significantly greater than either
drug alone (FLC, 40%; COL, 32% survival). By contrast,
adding colistin did not improve survival of the two strains with
lower tolerance (56% and 64% survival on FLC+COL vs 68%
and 72% survival on FLC alone). Overall, the tolerance level of
the C. albicans strain was relevant, with high FoG (more
tolerant) strains having more sensitivity to the drug
combination.
Combining Colistin with Fluconazole Increases Cell
Permeability to Propidium Iodide. To explore the
mechanism by which COL synergizes with FLC, we measured
the dynamics with which cells died in PI, first by microscopy
(Figures 3A,B and S6A), and determined the resulting CFU
(Figure S6B) and then quantitatively by flow cytometry
(Figures 3C and S7). As expected, cells not exposed to any
drug did not take up PI and had buds of all sizes, while dead
cells (killed with ethanol) stained brightly with PI (Figure 3A).
Flow cytometric analysis of the PI found that live cells
contained <239 AU (Figure 3B) and dead cells had >8931 AU
Figure 1. Colistin clears antifungal tolerance measured by disk
diffusion assays. (A) Images of disk diffusion assays using FLC disks
(25 μg/disk) with strain SC5314, performed without (left) or with
(right) the addition of COL (64 μg/mL) and imaged after 24 and 48
h (upper and lower panels, respectively). (B and C) Summaries of
disk diffusion assays quantified by diskImageR10 for the radius of the
zone of inhibition (RAD20) (left panels, in mm) and the fraction of
growth (FoG, right panels) in the absence (light blue dots) and
presence (dark blue dots) of fluconazole. Red dots, mean; red error
bars, standard deviation. (C) Assays performed with C. albicans
isolates having a range of different genetic backgrounds (see Table
1).7 (D) To test viability of cells across the plate in lower panel (A),
this plate was transferred to a YPAD plate with no drug by replica-
plating and imaged after 24 h. n = 3 biological and 2 technical
replicates per isolate.
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of fluorescence. In general, cells exposed to only one of the
drugs (FLC or COL) appeared very similar to untreated live
cells (Figure 3A, green arrow), with intact membranes. This is
consistent with the static nature of FLC and the fact that COL
does not have substantial antifungal activity at clinically
relevant drug concentrations.30
A small proportion of these cells did have discernible, but
low levels of PI staining (Figure 3A, right panel, pink arrow),
suggesting that they were partially permeable to the dye. The
cells that stained light pink appeared to have intact membranes
based on their DIC refraction, suggesting that, despite taking
up low amounts of PI, they were alive. By contrast, cultures of
cells treated with FLC+COL included live, unstained cells, the
light pink “permeable” cells with low levels of PI, as well as
many dead cells that stained brightly with PI (Figures 3A, right
panel, red arrow; Figures 3B and S6A). We do not know if
these light pink cells are able to continue growing over long
time periods or if they are cells that have begun to become
dye-permeable and will eventually lose membrane integrity.
Analysis of PI uptake over time using flow cytometry
revealed that the first cells that were permeable or dead
appeared after ∼1 h and that the proportion of permeable +
dead cells increased with time of incubation in the drug
combination (Figure 3B). Cells with an intermediate level of
PI staining (between 239 and 8931 AU by flow cytometry)
appeared to be viable, in that they retained normal cell shapes
(Figure 3A, pink arrow), appeared intact as judged by DIC
refraction, and had buds of all sizes, similar to the live cells
(green arrow).
Figure 2. Colistin acts synergistically with fluconazole. (A) Checkerboard assay measuring O.D.600 for combinations of with FLC (X axis) and COL
(Y axis) using 2-fold dilutions (0, 0.125, 0.25, 0.50, 1, 2, 4, 8, 16, 32, 64, and 128 μg/mL). Color bar indicates growth based upon O.D.600 (yellow
line, MIC50 for each drug combination) after 24h of growth. CFU determination gave similar results. (B) Growth curves (OD600) in 0.25 μg/mL
FLC without or with COL (0−128 μg/mL). (C) Checkerboard assay analyzed after 24 h of growth by flow cytometry. Cells were stained with
propidium iodide and analyzed by flow cytometry. The proportion of cells/mL in drug normalized to the number of cells/mL at 0 FLC and 0 COL
is illustrated (left panel, purple). The proportion of live cells (middle), and the proportion of dead cells (right) out of the total cells in a given well
were determined from the PI fluorescence (<239 AU for live cells) and >8931 AU for dead cells). (D−F) G. mellonella survival curves. Larvae were
inoculated with 5 × 104 cells/larvae. Two hours postinfection, larvae were treated with water only (black line), a single dose of FLC alone (0.0125
μg, light blue), COL alone (0.8 μg, gray), or FLC+COL (0.0125 μg and 0.8 μg, respectively, dark blue). Survival was recorded every 24 h for 5
days. Each group represents 50 larvae (N = 50). Larvae were infected with (D) lab SC5314, (E) low FoG strain YJB-T3016, or (F) highly tolerant
strain YJB-T3023. There was no significant difference between larvae treated with FLC alone or FLC and COL in either SC5314 or low FoG (p =
0.2154 and p = 0.11, respectively). There was a significant increase in survival of Galleria inoculated with the highly tolerant strain and treated with
the combination compared to FLC alone (p < 0.001 log-rank).
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Using flow cytometry, we quantified intracellular PI
fluorescence dynamics over 3 h after the addition of PI
(Figure 3B). As expected, the proportion of dead cells (PI
staining > 8931 units) increased with increasing amounts of
the two drugs. In all FLC+COL treatments, dead cells first
appeared at ∼60 min after adding the two drugs. Notably, the
number of cells that were partially permeable to PI (239−8931
AU) was evident in all combinations of FLC+COL
concentrations (Figure 3C). Together, these results indicate
that combining FLC and COL synergistically increases cell
permeability as well as cell death, two effects rarely seen with
either drug alone.
To determine whether FLC+COL caused a general effect on
cell permeability, we tested cell permeability in other stains,
such as mitotracker green, which enters cells and stains
mitochondrial membranes. The fluorescence intensity of
intracellular mitotracker green became far brighter in the
FLC+COL drug combination (P-value < 0.012) compared to a
slight increase in FLC alone (P-value < 0.07) relative to no
drug or COL only controls (Figure S7), suggesting that its
permeability was increased in the FLC+COL treated cells. By
contrast, no significant change in the intensity of calcofluor
white staining of the outer cell wall (which does not require
membrane permeabilization) was detectable (P-value > 0.4−
0.7, Figure S7), indicating that the change does not affect the
ability of the cell wall to bind calcofluor. Thus, the FLC+COL
combination appears to generally affect plasma membrane
permeability, allowing more stain, and perhaps more drug, to
enter the cells.
Fluorescent antifungal drug probes facilitate studies of drug
uptake and intracellular localization. We established a series of
fluorescent azole probes,39−41 including azole-dansyl and
azole-Cy5, both of which localize primarily to the mitochon-
dria, suggesting that some antifungal azole drugs may
accumulate in the mitochondria.39 These probes are also
useful for measuring net intracellular azole concentrations.
Because FLC+COL together cause a general increase in cell
permeability (e.g., permeability to mitotracker green), we asked
if COL also affects the ability of FLC to cross the cell
membrane. For this, we used azole-Cy5, a fluorescent azole
antifungal probe that retains antifungal activity, is readily taken
up by cells, and can be quantified by flow cytometry.39 Adding
COL to azole-Cy5 accelerated the rate of Cy5-azole uptake by
2-fold after 30 min of COL addition, relative to the level of the
probe uptake in the absence of COL (Figure S5). This implies
that the FLC+COL combination causes cells to reach higher
intracellular concentrations of the azole, presumably because of
increased membrane permeability.




alias genotype species source
YJB-T1 SC5314 wild-type C. albicans J. Ernst
YJB-T50 BG2 wild-type C. glabrata 54
YJB-T99 Wu284 wild-type C. dubliniensis 55
YJB-T48 660 wild-type C. tropicalis P. T. Magee
YJB-T90 ATCC22109 wild-type C. parapsilosis 56
YJB-T361 L26 MTL a/a C. albicans 57
YJB-T363 P87 MTL a/a C. albicans 57
YJB-T367 GC75 MTL alpha/alpha C. albicans 57
YJB-T379 P78042 MTL a/alpha C. albicans 57
YJB-T487 T101 MTL a/a C. albicans 58
YJB-T512 AM2003.0165 MTL α/α C. albicans 58
YJB-T111 wild-type figure isolate Saccharomyces
cerevisiae
59
YJB-T113 wild-type vineyard isolate S. cerevisiae 59
YJB-T47 wild-type clinical isolate Candida
guilliermondii
60
YJB-T1135 erg11D3−2 ura3Δ::λimm434/ura3Δ::λimm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG,erg11/
erg11
C. albicans 61
YJB-T3 FH5 Clinical series isolate, acquired i(5L) C. albicans 62
YJB-T4 FH8 FH5, i(5L) with distal deletion C. albicans 62
YJB-T572 BWP17 ERG11 ura3Δ::λimm434/ura3Δ::λimm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG ERG11-
URA2::RP10 locus
C. albicans this study
YJB-T573 YMG9517 FH5. erg11::NAT1 C. albicans 63
YJB-T532 DSY3987 ura3Δ::FRT/ura3Δ::FRT, TAC1-5/TAC1−5, ERG11-5/ERG11-5, RP10::Clp10 C. albicans 29
YJB-T736 SN152 SC5314 leu2Δ/leu2Δhis1Δ/his1Δarg4Δ/arg4ΔURA3/ura3Δ::imm434 IRO1/
iro1Δ::imm434
C. albicans 64
YJB-T737 BV06 SN152 erg2Δ::C.d.HIS1/erg2Δ:C.m.LEU2 C. albicans 65
YJB-T738 BV07 SN152 erg3Δ::C.d.HIS1/erg3Δ:C.m.LEU2 C. albicans 65
YJB-T739 BV08 SN152 erg4Δ::C.d.HIS1/erg4Δ:C.m.LEU2 C. albicans 65
YJB-T740 BV09 SN152 erg5Δ::C.d.HIS1/erg5Δ:C.m.LEU2 C. albicans 65
YJB-T741 BV10 SN152 erg6Δ::C.d.HIS1/erg6Δ:C.m.LEU2 C. albicans 65
YJB-T742 BV11 SN152 erg3Δ::C.d.HIS1/erg3Δ:C.m.LEU2 erg11Δ:C.d.ARG4/erg11Δ/C.d.ARG4 C. albicans 65
YJB-T743 BV12 SN152 erg24Δ::C.d.HIS1/erg24Δ:C.m.LEU2 C. albicans 65
YJB-T3015 SC5314 direct wild-type parent of YJB-T3016 and YJB-T3023 C. albicans R. Bennett
YJB-T3016 Low FoG YJB-T3015 passaged 12 days in YPD without drug A C. albicans J. Ene
YJB-T3023 High FoG YJB-T3016 passaged 12 days in YPD + 1 μg/mL fluconazole D C. albicans J. Ene
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Colistin Synergizes with Mutants in the Ergosterol
Biosynthesis Pathway. Colistin generally permeabilizes the
membranes of Gram-negative bacteria due to its high LPS
affinity and is therefore far less effective for Gram-positive
bacteria and eukaryotic membranes. Furthermore, COL does
not synergize with intracellular drugs such as 5-fluorocytosine
(Figure S3); thus, the mechanism of synergy with FLC cannot
be simply because COL increases yeast membrane perme-
ability. However, it was possible that COL has a secondary
effect that simply synergizes with azole antifungals. To test the
hypothesis that FLC causes membrane defects that synergize
directly with colistin-mediated membrane permeabilization, we
asked if C. albicans mutants lacking genes in the yeast
membrane ergosterol synthesis pathway42,43 (e.g., ERG2,
ERG3, ERG4, ERG5, ERG6, ERG11, and ERG24) are sensitive
to COL in the absence of FLC (Figure 4A).
Indeed, colistin reduced the growth of ergosterol bio-
synthetic mutants (erg11, erg3erg11, erg24, and erg2). This
suggests that it is changes in membrane ergosterol that make
cells more sensitive to colistin. Less dramatic effects were
evident with mutants encoding enzymes further downstream in
the ergosterol biosynthesis pathway.
FLC resistance and tolerance of the ERG mutants was
assessed with disk diffusion assays in the absence or presence
of COL (Figure S8A). Strains with erg6 or erg11 mutations
were resistant to FLC and were hypersensitive to COL (no
growth at all in the plate). Other erg mutants were more
susceptible to FLC and less sensitive to COL (Figure S8),
roughly as a function of their distance from erg11 in the
pathway. Similar results were seen when comparing the
proportion of cells inhibited as a function of COL
concentration (Figure 4B) using a population analysis profile
assay (Figure 4B). Together, these results indicate that the
depletion of ergosterol, either through azole treatment or
relevant erg mutations, increases the sensitivity of C. albicans
cells to COL. In addition, they highlight that the mechanism of
FLC+COL synergy is not due to increased amounts of
intracellular FLC. Rather, reduced membrane ergosterol
appears to increase cell vulnerability to COL, presumably
because of the altered membrane composition.
Figure 3. FLC+COL combination increases cell permeability, death,
and fluconazole uptake. (A) Microscopy of cells treated with 0.25 μg/
mL FLC (as in Figure 2A) and stained with PI. Green arrow, live
cells; pink arrow, permeable cells; red arrow, dead cells. DIC Images
overlaid on mCherry channel. Bar, 10 μm (143px). Images were taken
after 24 h of growth in the absence or presence of FLC. (B) PI
permeabilization after 3 h of drug exposure. Increase in cell
permeability over time for no drug, 32 μg/mL COL and 4 μg/mL
FLC + 32 μg/mL COL. Y-axis represents number of cells, and X-axis
represents PI intensity in 3 h exposure time point. (C) Following drug
exposure for 3 h, logarithmic cultures were analyzed at 15 min
interval, and cells were classified as live (green), permeable (pink), or
dead (red) using gating thresholds as described in the text. Flow
cytometry of PI stained for 3 h, at 15 min intervals. Increased levels of
permeable cells (pink) were particularly evident in FLC+COL treated
cultures. Left panel, no drug; right three panels, cells exposed to 32
μg/mL COL in the presence of 0, 4, or 8 μg/mL FLC. Examples of
similar experiments at different COL concentrations are in Figure S7.
Green, live, PI-impermeable cells; pink, PI-permeable cells; red, highly
PI-permeable dead cells. (D) Fluorescence microscopy cells treated
with Cy5-azole (1 μg/mL)39 and 32 μg/mL COL and then stained
with Mitotracker green, a dye that must cross the plasma membrane
to stain mitochondrial membranes, for 30 min. Size bar is 10 μm.
Figure 4. Colistin is cidal to mutants defective in early stages of
ergosterol biosynthesis. (A) General scheme of the C. albicans
ergosterol pathway43 (B) Analysis of subpopulation growth for
ergosterol biosynthesis mutants from 0 to 320 μg/mL of colistin for
24 h. Colors correspond to panel (A), with the wild-type parent strain
shown in the darkest shade of green. (C) Mutations in some ERG
genes cause increased cell permeability (top panel), that results in
increased cell death upon exposure to COL (64 μg/mL). Proportion
(0−100%) of live (green), dead (red), and permeable (pink) cells in
the absence (upper panel) and presence (lower panel) of COL for 16
h. Parental and erg mutant strains (with colors indicated in (A)) were
stained with PI and fluorescence was measured by flow cytometry.
Live cells (no PI staining (<239 AU), green), permeable cells (low PI
staining (>239 and <8931 AU, pink), and dead (high PI staining
(>8931 AU, red) with color scheme as in Figure 3C.
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To ask if colistin increases cell death in the erg mutants, as it
does with FLC, we quantified intracellular PI levels in the erg
mutants using flow cytometry. In the absence of drugs, almost
all cells were alive and impermeable. In the erg6, erg11, and
erg24 mutants, there was a small proportion of permeable cells
(up to 10%) and very small proportions of dead cells (Figure
4C). Importantly, adding COL to these mutants greatly
increased the proportion of dead cells (∼16−60%), with more
modest increases in the proportion of permeable cells (∼18−
27%, Figure 4C).
The analysis of erg mutants provides interesting insights into
the role of ERG3. First, while the erg3 mutant grew in the
presence of FLC alone, it grew slowly in general and, when
COL was present, the region near the FLC disk was highly
sensitive to COL (Figure S8A). This is reminiscent of the
clearance of tolerance by other adjuvants in wild-type cells and
suggests Erg3 has a more prominent role in FLC tolerance
than in bona f ide resistance.44,45 However, unlike wild-type
cells, erg3 mutants remained largely viable in the presence of
FLC+COL, while erg11erg3 mutants, like erg11 mutants, were
largely killed by COL (Figure 4B and C). This indicates that
erg11 is epistatic to erg3 and that erg3 mutations do not rescue
the sensitivity to COL conferred by erg11 deletion. Rather, it
appears that the sensitivity of wild-type cells to FLC+COL is
largely a function of ergosterol depletion and is not highly
affected by the ability of Erg3 to produce toxic sterol
intermediates. Taken together, these results imply that COL
not only increases the amount of FLC that enters cells (Figure
3) but also permeabilizes, and ultimately kills, cells whose
membranes have reduced ergosterol content (Figure 4).
Colistin Acts More Rapidly on Fluconazole Pretreated
Cells. Fluconazole inhibits ergosterol biosynthesis by inhibit-
ing the lanosterol 14α-demethylase encoded by ERG11;
however, ergosterol depletion requires several hours to slow
growth and affect cell morphology.46 Since the combination of
COL with FLC increased FLC uptake, cell permeabilization,
and death, and since this is a consequence of ergosterol
depletion, we next asked whether the dynamics of colistin’s
mechanism of action were faster than those of the mechanism
of action of FLC. We compared the activity of COL added to
fluconazole-pretreated cells with the activity of FLC added to
colistin-pretreated cells by measuring PI levels over time after
the addition of the second drug. Cells were 16 h in medium
with the first drug and then we added medium without drug,
with COL or FLC alone, or with both drugs together. PI
intensity was measured 5 h after the addition of the second
drug.
As expected, control cells exposed to no drug or to COL
alone were not permeable to PI (Figure 5). Adding COL to
cells pre-exposed to FLC (Figure 5), or to cells initially treated
with FLC+COL (Figure 5), reduced viability within the first
30 min of treatment (Figure 5). By contrast, when adding FLC
to cells pre-exposed to COL, growth reduction was seen only
after ∼90 min (Figure 5). Importantly, when COL was added
to cells initially exposed to FLC, the reduction in viability
occurred before the first measurement (at 30 min following the
addition of COL) (Figure 5). Thus, COL rapidly perme-
abilizes cells pretreated with FLC more rapidly than it
permeabilizes cells when added together with FLC. This
suggests that COL not only increases FLC entry into cells, but
that COL may have a more dramatic effect on viability in cells
depleted for ergosterol.
Colistin Interacts with Membrane Phospholipids.
While COL specifically binds bacterial lipopolysaccharide
(LPS) in Gram-negative bacteria, in Gram-positive bacteria,
it acts as a positively charged detergent, albeit at much higher
concentrations than those required to eradicate Gram-negative
pathogens.47 To ask if the antifungal activity of COL also is
dependent upon its peptide charge, we tested three additional
membrane-disrupting antimicrobials with different net charges
for their ability to synergize with FLC (Figure S9). Similar to
COL (charge +547), RB163, a cationic amphiphile-derived
from the aminoglycoside antibiotic tobramycin48 (compound 3
in ref 48) synergized with FLC (FICI = 0.28 with 0.125 μg/
mL FLC and 4 μg/mL RB163). By contrast, daptomycin
(charge −3)49 (Figure S9C) did not augment the activity of
FLC. These results are consistent with the idea that, as for
Gram-positive bacteria, in C. albicans, positive charge may be
an important feature required for COL to disrupt ergosterol-
depleted membranes.
COL binds with high affinity to LPS, a lipid absent from
eukaryotic membranes.50 To ask if COL nonspecifically binds
Figure 5. Order of addition of the two drugs affects the dynamics of FLC+COL cidality. SC5314 cells initially were pre-exposed to one drug; in all
cases, 10 μg/mL FLC or 32 μg/mL COL was used in preincubation. After 16 h of pre-exposure, one drug was added (10 μg/mL FLC or 32 μg/mL
COL) together with PI, and intracellular PI staining was measured at 30 min intervals. The proportions of live cells (intracellular PI staining < 239
AU, left), permeable cells (PI staining > 239 and < 8940 AU, center), and dead cells (PI staining > 8940 AU, right) are illustrated. Black dashed
line indicates the time that the second drug was added (t = 0). Cells pre-exposed to COL (light green) to which FLC was added (dark green). The
proportion of live cells dropped after >120 min. Cells pre-exposed to FLC (lighter blue) to which COL was added (dark blue). Upon the addition
of COL, the proportion of live cells dropped almost immediately, within <60 min. Note that the time required for reduced permeability in
stationary cells, here, was longer here than the time required in log phase cells in Figure 4C. The “no drug” data was identical to the COL line and
is illustrated slightly above it to ensure it is visible. The dead cell control (cells fixed with ethanol) is shown as a dark red line.
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negatively charged membrane lipids present in yeast
membranes, we performed a fluorescence displacement assay
that discriminates between subtle differences in the binding of
small molecules to the lipid A of core LPS, as well as to other
phospholipids (see Methods). Indeed, COL was able to bind
to phosphatidylinositol (PI), phosphatidyl-L-serine, and
phosphatidylethanolamine, albeit with affinities 2-fold lower
than its affinity for LPS (Figure S10). This supports the idea
that COL has the potential to bind eukaryotic lipids in the
plasma membrane. Altogether, it suggests that COL binds
fungal plasma membranes to a greater degree when they are
depleted of ergosterol, generating increased permeability to
antifungal drugs, vital dyes, and other intracellular stains. Thus,
we propose that COL, when combined with FLC, acts
synergistically and increases drug cidality via the permeabiliza-
tion of ergosterol-depleted membranes.
■ DISCUSSION
This study addressed the mechanism by which clinically
feasible concentrations of COL, a potent anti-Gram-negative
lipopeptide antibiotic, enhance the antifungal activity of
fluconazole, the most widely used antifungal drug. We first
confirmed earlier reports29,30 that colistin indeed synergizes
with fluconazole against a range of C. albicans isolates, as well
as against other non-albicans Candida species although the
synergy with azoles is weaker than the synergy with
echinocandins. Importantly, the effect of colistin on
fluconazole tolerance is far more pronounced than that on
resistance. Furthermore, the amount of colistin required to
augment fluconazole and cause cell damage and death (2 μg
colistin, Figure 2A and B) is well within the range of colistin
concentrations used to treat patients with bacterial infec-
tions,51,52 a critical distinction from many combination
therapies that work in vitro but are not amenable to clinical
use because of high toxicity in mammals. Consistent with this,
colistin was particularly effective at augmenting the effect of
fluconazole on a highly tolerant C. albicans isolate. Colistin also
increased cell permeability and death in cells depleted for
ergosterol, either by azole drugs or by mutations affecting
critical steps in ergosterol biosynthesis. Finally, colistin can
bind eukaryotic membrane lipids. We propose that the
mechanism by which colistin exerts its antifungal activity is
likely similar to its activity in Gram-positive bacteria: via
membrane permeabilization that is dependent upon the highly
cationic nature of the peptide and the negative charge of
membrane. Thus, we posit that colistin binds and disrupts
eukaryotic membranes more effectively if they are depleted of
ergosterol and/or if plasma membrane integrity is perturbed.
Colistin Largely Reduces Fluconazole Tolerance, In
Vitro and In Vivo. By directly assaying tolerance as well as
resistance, the colistin-mediated reduction in fluconazole
resistance was relatively modest: an average of 0.4 mm
increase in the radius of the zone of inhibition, irrespective of
the initial susceptibility level of the strain. Nonetheless,
fluconazole enables colistin to affect fungal membranes
resulting in cell death instead of cell arrest, and colistin
reduced fluconazole tolerance to approximately basal levels,
such that the original FoG level in FLC correlated with the
reduction in FoG level in fluconazole plus colistin (R2 = 0.91).
This result was seen with diverse C. albicans and non-albicans
Candida isolates and is similar to what was previously seen
with other adjuvant drugs when combined with fluconazole.7
Based on a study of patient isolates with high and low
tolerance levels,7 fluconazole plus colistin, like other
fluconazole-adjuvant combinations, would be most effective
for treating infections caused by isolates with high fluconazole
tolerance. Indeed, the fluconazole plus colistin combination
increased the survival of G. mellonella infected with high
tolerance strains most dramatically. Accordingly, the use of
combination approaches that largely affect tolerance would
require that clinical assays measure not only drug resistance,
but also tolerance quantitatively, whether by disk assays
analyzed by diskImageR or by broth microdilution assays.7,10,11
Colistin Increases Cell Permeability and Cidality of
Ergosterol-Depleted Cells. Adding colistin to fluconazole
increases the proportion of dead and PI-permeable cells in a
concentration-dependent manner (Figure 3C). Furthermore,
the fluconazole plus colistin combination is cidal, at drug
concentrations as low as 0.25 μg/mL of fluconazole with 2 μg/
mL colistin (Figure 2), as determined by replica plating
(Figure S2) as well as PI staining (Figures 2C and 3).
Importantly, we found that PI staining could be used to
identify permeable, yet viable, cells in addition to the classic
distinctions made between live (unstained) and dead (brightly
stained) cells. The interpretation of permeability in the low-to-
intermediate level of intracellular PI staining, is based upon cell
refractivity and morphology, as well as on colony counts that
suggest these cells continue to grow and form colonies.
Nonetheless, we cannot rule out the possibility that at least
some of these cells may be on their way to cell death. Whether
they necessarily die or are able to recover remains to be
determined.
The ability of colistin to permeabilize cells is associated with
its ability to kill them. This appears to be due, in part, to
colistin increasing the ability of azole probes to enter cells. In
addition, in cells pretreated with fluconazole, COL accelerates
cell permeability and mortality within 30 min (Figure 5).
Similarly, cells lacking enzymes critical for ergosterol synthesis
die when colistin is added (Figure 4) and this occurs via a cell
permeabilization that appears similar to that seen with
fluconazole plus colistin. Consistent with this, in Burkholderia
cepacia, disruption of genes that encode enzymes required for
the synthesis of hopinoids, analogues of eukaryotic steroids, are
far more sensitive to polymyxin B.53 Taken together, these
results indicate that the azole treated cells are more sensitive to
colistin because not only because colistin increases the
intracellular fluconazole concentration, but because ergosterol
depletion by fluconazole renders the cells more vulnerable to
permeabilization by colistin.
We propose that the synergism of fluconazole with colistin
occurs through a series of steps. First, fluconazole inhibits
ergosterol biosynthesis, resulting in the depletion of membrane
ergosterol. Second, ergosterol depletion alters membrane
properties, making the membrane more susceptible to
colistin-mediated membrane permeabilization, thereby increas-
ing the intracellular concentrations of azoles and other
molecules. Third, the detergent activity of COL permeabilizes,
and thereby kills, more cells. Importantly, these synergistic
activities occur in a dose-dependent manner, such that colistin
can be used together with fluconazole and other azoles at low,
clinically feasible, concentrations.
■ CONCLUSION
Colistin synergizes with fluconazole to permeabilize cell
membranes, which leads to higher cidality with drug
combinations used at low, clinically relevant concentrations.
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The drug combination is particularly effective against isolates
that exhibit fluconazole tolerance, both in vivo and in vitro,
which is achieved by activation of stress response pathways and
reduction in intracellular drug concentrations.7 The interaction
appears to be due to colistin binding plasma membrane lipids
and is more effective in cells depleted of ergosterol, either
pharmacologically (via an azole antifungal) or genetically, via
mutations in ergosterol biosynthesis.
■ METHODS
Growth Conditions. Strains used in this study are listed in
Table 1. Experiments were conducted with C. albicans standard
lab strain SC5314, unless noted otherwise. Cells were grown to
log phase in liquid casitone (casitone, yeast extract, sodium
citrate dehydrate, glucose plus 40 mg/L adenine and 80 mg/L
uridine; Sigma). Cultures were shaken at 30 °C in 5 mL of
YPAD overnight. Drug-exposed cultures were diluted 1:100 for
2−3 h in casitone followed by drug addition. Drugs were
diluted in water (posaconazole (Sigma-Aldrich SML2287,
>98%), colistin (Glentham Life Sciences GA9867, ≥19 000 U/
mg), amphotericin B (TOKU-E, ≥95%), 5-fluorocytosine
(Sigma-Aldrich F7129, ≥99%); ethanol (terbinafine T8826,
≥98%), fluconazole (Sigma-Aldrich F8929, ≥98%, ketocona-
zole (Sigma-Aldrich K1003, ≥99%), miconazole (Fischer
Bioreagents, 98%), clotrimazole (Glentham Life Sciences,
GA8137), caspofungin diacetate (Sigma-Aldrich SML0425,
≥19 000 IU/mg), anidulafungin (Sigma-Aldrich SML2288,
≥97%) myriocin (Sigma-Aldrich M1175, ≥98%), amphoter-
icin B (A2411, ∼80%), daptomycin (Sigma-Aldrich D2446,
≥90%), RB16348 (≥95%)) or DMSO (natamycin, Sigma-
Aldrich, ≥95%). Casitone solid media (casitone liquid plus 10
g/L agar (Formedium, Ltd.)) was used for the disk assay
method. Colistin (GA9867, Glentham Life Sciences, ≥19 000
U/mg) was added to agar media at a final concentration of 64
μg/mL.
Disk Assays. Strains were streaked from frozen culture
onto YPAD agar and incubated overnight at 30 °C. Two to
three colonies were picked into 1 mL of 1× PBS solution, and
optical density (OD600) was determined with an Infinite M200
PRO Tecan instrument. OD600 was adjusted to 0.01 (10
6 cells/
mL) through dilution with 1× PBS, and 200 μL of diluted
culture from each strain was plated onto 15 mL casitone plates
and spread using sterile beads (3 mm, Fisher Scientific). After
the plates had dried, a single 25 μg drug disk (6 mm diameter,
Becton, Dickinson and Company, USA) was placed in the
center of each plate. Plates were incubated at 30 °C for 48 h.
Analyses of RAD and FoG were done by using the diskImageR
script.10
Population Analysis Profiling Assays. Fresh colonies
(2−3) were picked from strains grown overnight on YPAD
plates into 1 mL of 10% glycerol in 96-well plates, and cells
were diluted to 106 cells/mL based on OD600 measurements,
followed by 10-fold dilution series to reach 1000 cells/mL. A
volume of 10 μL was spotted to plates containing different
concentrations of COL or FLC ranging from 0 to 320 μg/mL.
Cells were counted manually, and the number of cells per
milliliter was calculated according to the dilutions and plotted
using R software (ggplot2).
Checkerboard Assays and Growth Curves. Two to
three colonies of strain SC5314 were picked into 1× PBS
buffer, OD600 was adjusted to 0.01 (10
6 cells/mL) with 1×
PBS, and cultures were then diluted to 103 cells/mL in casitone
media. Drugs were added in a double dilution grid ranging
from 0 to 128 μg/mL in 96 flat-well plate (BND003C,
ThermoFisher Scientific). For growth curves, checkerboard
assay plates as above were incubated in a Tecan Infinite
instrument for 48 h in 30 °C with shaking. OD600 was read
every 15 min. OD600 at 24 h was plotted with Java Treeview
software. FICI calculation was calculated as MIC(AB)/
MIC(A) + MIC(BA)/MIC(B); MIC(AB) − MIC50 of drug
A in the presence of drug B; MIC(A) − MIC50 of drug A;
MIC(BA) − MIC50 of drug B in the presence of drug A;
MIC(B) − MIC50 of drug B. FICI ≥ 0.5 was interpreted as
synergy.34
CFU Count. Colony forming units (CFUs) were used to
infer the cidality of fluconazole-colistin combinations at several
concentrations. SC5314 was grown overnight on YPD agar at
30 °C, and a checkerboard assay as described above was
performed. After OD600 was measured, 5 mL from the relevant
wells was serially diluted into YPD and plated onto YPD agar
such that individual colonies could be enumerated. Colonies
were counted, and final CFU was determined, following a 48 h
incubation at 30 °C.
Permeability Assay. Cells were grown in 3 mL liquid
casitone media with shaking at 30 °C overnight. Cultures were
diluted 1:100 and incubated for 2 h at 30 °C prior to initiating
drug exposure (no drug, 32 μg/mL COL, 10 μg/mL FLC, and
both drugs together at these concentrations) at 30 °C with
shaking. Samples collected over 16 h of growth were stained
with propidium iodide as follows. A volume of 20 μL from
each culture was added to 180 μL of TE 50:50 buffer (50 mM
TrisHCl Sigma-Aldrich) such that the final PI concentration
was 100 μg/mL. Flow cytometry data were collected from
5000−35 000 cells per time point using B2 laser excitation at
488 nm and emission at 614/50 nm on a MACSQuant
Analyzer 16 flow cytometer. Analysis was performed using
FlowJo 8.7 software.
Galleria Mellonella Survival Assay. The larvae of the
wax moth G. mellonella were obtained from Live Foods (U.K.).
Larvae were kept at room temperature (∼20 C) and used
within 3 days of arrival. Only healthy larvae, not showing any
darkening, were used. Ten larvae were randomly selected for
each group. The experiment was repeated five times (N = 50).
C. albicans (YJB3015 (low FoG), YJB3016 (low FoG), and
3023 (high FoG)) were grown overnight at 30 °C on YPD
agar. A final inoculum size of 5 × 106 CFU/mL as determined
by OD600 was prepared by diluting a sweep of colonies into
YPD liquid. A Hamilton syringe with a 28G needle was used to
inject each larvae with 10 μL of the inoculum (5 × 104 CFU)
via the bottom left proleg. Larvae were incubated at 30 °C for
2 h prior to a second injection into the bottom right proleg of
either water, FLC (1.25 μg/mL), COL (80 μg/mL), or FLC
+COL (1.25 μg/mL and 80 μg/mL, respectively). Larvae were
incubated at 30 °C for 5 days. Larval survival was assessed
every 24 h. A larva was considered dead if it had turned black-
gray and did not respond to physical stimuli. A trauma control
group (two injections of water) and drug-tolerance groups
(one injection of a drug condition and one of water) were used
as additional controls. A further control group that received no
injections was also used. 100% of larvae in these control groups
survived (data not shown). Statistical variation was determined
using the log-rank test.
Assaying Sequential Addition of Drugs. Cells were
grown in 3 mL of liquid casitone media with shaking at 30 °C
in tubes overnight. Cultures were diluted 1:100 and incubated
for an additional 2 h at 30 °C followed by OD600 measurement
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with a TeCAN Infinite instrument. OD600 was adjusted to 0.01
(106 cells/mL) with casitone media, and cells were grown in
four different conditions (no drug, 32 μg/mLCOL, 10 μg/mL
FLC and both drugs) for 16 h at 30 °C with shaking. After 16
h, the first measurement (0 min) was taken by adding 20 μL of
each culture to 180 μL of TE 50:50 buffer (50 mM TrisHCl
pH 8.0, 50 mM EDTA) containing PI at a concentration of
100 μg/mL (P4170 SIGMA Aldrich). At 30 min, drugs were
added. PI permeability was tested, as above, at 15 min intervals
for 3 h. Flow cytometry data were collected from 5000−35 000
cells per time point by using B2 laser excitation (excitation at
488 nm and emission at 614/50 nm) on a MACSQuant flow
cytometer. Analysis was performed using FlowJo 8.7 software.
Staining. Log phase cell cultures were exposed to different
drugs at 30 °C, for times indicated in figure legends. Cells were
isolated from a log phase culture and warmed to 37 °C.
Mitotracker Green FM (c.n.M7514 ThermoFisher) was added
to a final concentration of 1 mM. Cells were incubated in the
dark for 0−120 min. Cells were then washed with 1× PBS
buffer and resuspended in SDC medium (0.17% yeast nitrogen
base with ammonium sulfate [Formedium], 2% glucose)
supplemented with amino and nucleic acids)66 containing 1
mg/mL calcoflour white (by Sigma-Aldrich) for imaging each
time point. DAPI (4′,6-diamidino-2-phenylindole, Sigma-
Aldrich) was suspended in double distilled water and added
to cells at 10 μg/mL final concentration in PBS with cells at 25
°C for 5 min.
Time Course Imaging/Microscopy. Cells in time course
experiments were washed and resuspended in SDC prior to
being imaged on glass slides with glass coverslips. Images were
collected using a Nikon Ti Eclipse microscope equipped with a
Nikon 1006, 1.4 NA, 100× objective and a Zyla 5.5 sCMOS
camera run by NIS elements Ar software. To image the stains,
we used the following filter sets: MitoTracker Green, 470 nm
excitation and 525/50 nm emission; calcofluor white and
DAPI, 365 nm excitation and 460/50 nm emission; and Azole-
Cy5, 585 nm excitation and 630/75 nm emission.
Flow Cytometric Analysis of Azole-Cy5 Uptake. Cells
were grown in 3 mL of liquid casitone medium at 30 °C with
shaking overnight. Cultures were diluted 1:100 and incubated
for an additional 2 h at 30 °C. Azole-Cy5 was added (1 μg/mL
final concentration), and cultures were incubated for an
additional 0−180 min with shaking at 30 °C. For for uptake
analysis, cells were harvested every 30 min and diluted 1:10 TE
50:50 buffer (50 mM TrisHCl pH 8.0, 50 mM EDTA), using
25 000−35 000 cells per time point on a MACSQuant flow
cytometer using 561 nm excitation and 661/20 nm emission
(Y3 laser). Data were analyzed with FlowJo8.7 software.
Lipid Binding Assay. Lipid binding was measured using a
fluorescence displacement assay that measures the fluorescent
signal of BODIPY-cadaverine and discriminates between subtle
differences in the binding of small molecules to the lipid A core
of lipopolysaccharide (LPS). It measures competitive displace-
ment by compounds displaying lipid A affinity. As BODIP-
cadaverine binds to other phospholipids, this fluorescence
displacement assay can be used to measure the binding of
small molecules to phospholipids other than LPS.67,68
Stock solutions of lipids (Sigma-Aldrich) (LPS 5 mg/mL in
H2O; PE, 5 mg/mL in DMSO/H2O; PI, 5 mg/mL in H2O and
PS 1 mg/mL in H2O) and BODIPY-TR-cadaverine (500 μM)
were prepared in Tris buffer (pH 7.4). Lipid stocks and
BODIPY-TR-cadaverine stock were mixed and diluted in Tris
buffer to a final volume of 100 mL, yielding final
concentrations of 50 μg/mL of lipid and 5 μM BODIPY-
TR-cadaverine. To each well of the 96-well plate, 40 μL of Tris
buffer with COL or FLC was added using double dilutions
starting from 2 mM, followed by the addition of 40 μL of
BODIPY-TR-cadaverine−lipid mixture. Fluorescence was
measured on a TECAN Microplate reader (infinite F200
PRO) at 25 °C using excitation and emission wavelengths of
580 and 620 nm, respectively (monochromatic band pass of 5
nm). Data were collected from two independent experiments,
with three replicates per experiment.
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